English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18055/20253 (89%)
Visitors : 24694265      Online Users : 476
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/29623


    標題: Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial
    作者: Huang, Charles Lung-Cheng
    Hwang, Tzung-Jeng
    Chen, Yi-Hsing
    Huang, Guan-Hua
    Hsieh, Ming H.
    Chen, Hsiu-Hsi
    Hwu, Hai-Gwo
    貢獻者: 社會工作系
    關鍵字: agitation
    haloperidol
    injection
    lorazepam
    olanzapine
    schizophrenia
    日期: 2015-05
    上傳時間: 2016-04-19 19:02:23 (UTC+8)
    出版者: Elsevier Taiwan
    摘要: Background/Purpose: To compare the efficacy and safety profile between intramuscular (IM) olanzapine and IM haloperidol plus IM lorazepam in acute schizophrenic patients with moderate to severe agitation.Methods: This was a prospective, randomized, open-label study. Acutely agitated patients with schizophrenia or schizoaffective disorder (n = 67) were randomized to receive 10 mg IM olanzapine (n = 37) or 5 mg IM haloperidol plus 2 mg IM lorazepam (n = 30). Agitation was measured with Positive and Negative Syndrome Scale Excited Component (PANSS-EC) and AgitationeCalmness Evaluation Scale (ACES) during the first 2 hours and at 24 hours after the first injection. Safety was assessed using the SimpsoneAngus Scale and Barnes Akathisia Rating Scale and by recording adverse events at 24 hours following the first injection. The Clinical Global Impression-Severity scale was also rated.Results: The PANSS-EC scores decreased significantly at 2 hours after the first injection in both groups (olanzapine: -10.2, p < 0.001; haloperidol + lorazepam: -9.9, p < 0.001). Haloperidol plus lorazepam was not inferior to olanzapine in reducing agitation at 2 hours. There were no significant differences in PANSS-EC or ACES scores between the two groups within 2 hours following the first injection. The frequencies of adverse events and changes in Clinical Global Impression-Severity, SimpsoneAngus Scale, and Barnes Akathisia Rating Scale scores from baseline to 24 hours showed no significant differences between the groups.Conclusion: The findings suggest that IM haloperidol (5 mg) plus lorazepam (2 mg) is not inferior to IM olanzapine (10 mg) in the treatment of acute schizophrenic patients with moderate to severe agitation. Copyright (C) 2015, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
    關聯: Journal of The Formosan Medical Association, v.114 n.5, pp.438-445
    Appears in Collections:[社會工作系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML2028View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback